Central role for PICALM in amyloid–β blood–brain barrier transcytosis and clearance
Sagare, Abhay P.
Halliday, Matthew R.
Winkler, Ethan A.
Owens, Nelly Chuqui
Rege, Sanket V.
Miller, Carol A.
Schneider, Julie A.
Ichida, Justin K.
Zlokovic, Berislav V.Note: Order does not necessarily reflect citation order of authors.
MetadataShow full item record
CitationZhao, Z., A. P. Sagare, Q. Ma, M. R. Halliday, P. Kong, K. Kisler, E. A. Winkler, et al. 2015. “Central role for PICALM in amyloid–β blood–brain barrier transcytosis and clearance.” Nature neuroscience 18 (7): 978-987. doi:10.1038/nn.4025. http://dx.doi.org/10.1038/nn.4025.
AbstractPICALM is highly validated genetic risk factor for Alzheimer’s disease (AD). Here, we report that PICALM reductions in AD and murine brain endothelium correlate with amyloid–β (Aβ) pathology and cognitive impairment. Moreover, Picalm deficiency diminishes Aβ clearance across the murine blood–brain barrier (BBB) and accelerates Aβ pathology that is reversible by endothelial PICALM re–expression. Using human brain endothelial monolayer, we show that PICALM regulates PICALM/clathrin–dependent internalization of Aβ bound to the low density lipoprotein receptor related protein–1, a key Aβ clearance receptor, and guides Aβ trafficking to Rab5 and Rab11 leading to Aβ endothelial transcytosis and clearance. PICALM levels and Aβ clearance were reduced in AD–derived endothelial monolayers, which was reversible by adenoviral–mediated PICALM transfer. iPSC–derived human endothelial cells carrying the rs3851179 protective allele exhibited higher PICALM levels and enhanced Aβ clearance. Thus, PICALM regulates Aβ BBB transcytosis and clearance that has implications for Aβ brain homeostasis and clearance therapy.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:24983849
- HMS Scholarly Articles